Director/PDMR Shareholding

RNS Number : 2908U
GlaxoSmithKline PLC
16 January 2017
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr M M Slaoui

b)

Position/status

Chairman, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

   

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's US Deferred Performance Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$39.01

266.485

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D E Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

 

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's US Deferred Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$39.01

353.083

$39.01

5.441

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 358.524

 

$39.01

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHDQLFFDFFBBBF

Companies

GSK (GSK)
UK 100

Latest directors dealings